semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diarrhea Medullary Thyroid Cancer Patients with medullary thyroid cancer Men and women from all ethnic and racial groups Diarrhea ( >=3 loose bowel movements per day) Duration of diarrhea of at least 1 week  Patients with MEN 2b (since these patients may have megacolon) Patients taking any clay products History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up Patients who cannot comply with medications Patients whose current medication schedule would not permit an approximate 2 hour window between administration of CASAD and other scheduled medications Pregnancy or lactation Patients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pseudomonas Aeruginosa Ventilation Acquired Pneumonia Patients> 18 years hospitalized in the intensive care unit with more than 72 hours of mechanical ventilation Presenting a positive bacteriological sample P. aeruginosa  Minors Pregnant or lactating women Patients under guardianship, under judiciary placement, or hospitalized without their consent Patients not affiliated to a social security scheme Long-term corticosteroid therapy (> 2mg/kg or> 1 month before the onset of established infection suspected) Ongoing chemotherapy, AIDS, transplant patient under immunosuppressive drugs Bedridden patient or therapeutic decision at ICU arrival
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Pneumonia ambulant aquired pneumonia with typically radiological signs hospitalisation at medical clinic I, university hospital Aachen age at least > 18 years CRB-65 score > 1 CRP> 60mg/l fever lung sounds audible by stethoscope legal capacity and being able to understand and to follow the instructions of the study staff being able to consent and being able to understand the importance and the consequence of the study not being accomondated in an institution  pneumonia acquired in a hospital artificial respiration or other means for supporting respiration allergic reaction because of skin contact with polymers pregnancy or breast feeding
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Clostridium Difficile Infection Table 1. for Healthy Volunteers: 1. Healthy individuals without chronic gastrointestinal problems or using antisecretory medications. Table 2. for Clostridium difficile infection subjects: 1. Newly diagnosed first episode of CDI prior to being treated. Table 3  for Healthy Subjects: 1. Prior gastrointestinal surgery that has altered the anatomy of the esophagus, stomach, or small/large intestine including appendectomy and cholecystectomy. 2. Chronic daily use of any medications that could alter gastrointestinal secretory or motor function (see Table 2). 3. Gastrointestinal, cardiovascular, endocrine, renal, or other chronic disease likely to affect gastrointestinal motility (e.g., uncontrolled diabetes mellitus). 4. Females of childbearing age who are not practicing at least one form of birth control at least one month prior to starting the PPI or are pregnant or lactating (a pregnancy test will be performed on female subjects prior to PPI use). 5. Significant untreated psychiatric disease. Table 4. Prohibited Medications: 1. Antibiotics within 2 months of the stool sample collection. 2. Probiotics (e.g., Florastor, Align, Flora-Q, VSL#3, lactobacillus, bifidobacterium) within 2 weeks of the stool sample collection. 3. Fiber supplements (e.g., Metamucil, Citrucel, Benefiber), unless maintained on a stable dose for the last 3 months. 4. Chronic use of medications that alter gastric pH: proton pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole) and histamine2 receptor antagonists (e.g., cimetidine, famotidine, ranitidine). 5. Chronic use of medications that affect gastrointestinal motility and/or transit including prokinetic agents (e.g., metoclopramide (Reglan), tegaserod (Zelnorm), domperidone (Motilium), erythromycin), narcotic analgesic agents (e.g., methadone, fentanyl, oxycodone, codeine, morphine, hydromorphone), laxatives including mineral oil, anticholinergic agents (e.g., Bentyl, Levsin), and antidiarrheal agents (e.g., Kaopectate (donnagel), Pepto-Bismol (bismuth subsalicylate), Imodium (loperamide), Lomotil (atropine with diphenoxylate), codeine, tincture of opium)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.5-999.0,  Clostridium Difficile Infection Recipient 1. Older than 18 months of age 2. FMT procedure has been decided by the treating gastroenterologist and was based on: 1. Recurrent or relapsing CDI and Failure of standard medical therapy with metronidazole, vancomycin and fidaxomicin (over age 18 years. Fidaxomicin is not approved for <18years and insurance authorization may not be possible) At least 2 episodes of CDI requiring hospitalization 2. Moderate CDI not responding to vancomycin for at least a week. 3. Severe CDI with no response to vancomycin after 4 hours. 3. English speaking Recipient  Lack of informed consent/assent. 2. Not eligible for FMT procedure
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Primary Care Phase I VA patients who have had some experience with care receipt through technology (e.g., home telehealth, CVT, secure messaging with providers) A second group will be conducted with patients who have not had experience receiving care through technology There are no other specific and the investigators plan to recruit both male and female Veterans, as well as minorities. Phase II Veterans who receive care from VA and are comfortable using the Internet There are no other specific and the investigators plan to recruit both male and female Veterans, as well as minorities. Phase III Veterans who receive care from Hines VA or Jesse Brown VA in a primary care/PACT clinic No subjects will be excluded based on gender, race, or ethnicity (1) adult, age 18 or over (2) assigned primary care provider in PACT clinic  A history of dementia Blindness
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.0-14.0,  Japanese Encephalitis Children aged between 1 and 14 years who had clinically diagnosed encephalitis on the basis of history of fever that lasted less than 14 days, altered consciousness with or without a history of new onset seizures with CSF finding of white cell count less than 1000 cells/mm3 with no organisms on Gram stain and a CSF: plasma glucose ratio > 40% admitted in Kanti Children's Hospital and BP Koirala Institute of Health Sciences, Nepal  Asexual Plasmodium falciparum parasites in blood Coma appears secondary to other systemic condition, eg hepatic failure, cardiac failure, toxins Patients who have documented antibiotic treatment before admission and in whom partially treated bacterial meningitis appears more likely than encephalitis Children with simple febrile convulsions, defined as a single seizure lasting less than 15 minutes followed by full recovery of consciousness within 60 minutes Pregnant or breastfeeding females Children with a GCS of 3/15, who were receiving artificial ventilation without signs of spontaneous respiration, and with absent oculocephalic reflex
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Active C. Difficile Colitis Only VA patients will be eligible for the study if they have had a confirmed diagnosis of CDI that has been treated for 10-14 days with recommended doses of metronidazole or vancomycin and has either failed to respond, or has responded and relapsed within 4 weeks of the end of treatment. The diagnosis will be regarded as confirmed by the presence of diarrhea (>3 unformed stools in a 24-hour period for 2 successive days) and abdominal discomfort. The presence of fever, leukocytosis, and a serum albumin <3 gm/dL will be recorded but will not be necessary for the diagnosis. Patients will be included after they have given informed consent and signed the appropriate consent form that has been approved by the Baylor IRB  treatment with major immunosuppressive agents including prednisone >10 mg/day (or its equivalent), calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, lymphocyte-depleting biological agents, anti-tumor necrosis factor agents, and others; chemotherapeutic antineoplastic agents; decompensated liver cirrhosis; serum creatinine >4 or need for hemodialysis; presence of an active malignancy other than superifical skin cancer (eg, basal cell); HIV/acquired immune deficiency syndrome; recent bone marrow transplant, or other cause of severe immunodeficiency; requirement for concurrent antimicrobial therapy; contraindication for ultra-slim endoscopy including severe chronic heart or lung disease; a chronic bedridden state; and any other condition suggesting that life span will not be >1 yr. -
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Development of Clostridium Difficile Associated Diarrhea Any hospitalized patient who is age 19 or older and receiving antibiotics. -  Feeding tube in place Pregnancy Milk or soy allergy Sensitivity to lactose Immunocompromised defined as: 1. Absolute neutrophil count (ANC) ≤ 500 cells/mm3 2. HIV 3. Cancer patient receiving chemotherapy or radiation therapy 4. Immune deficiency 5. Post organ transplant Participants will be withdrawn from the study if they develop any of the during the hospitalization. -
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Irritable Bowel Syndrome (IBS) Female 18-65 years of age (inclusive) 2. Diagnosed with IBS based on the following (Rome III criteria) Symptom onset at least 6 months prior to diagnosis, and Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and Abdominal discomfort or pain associated with two or more of the following at least 25% of the time improvement with defecation onset associated with a change in frequency of stool/defecation onset associated with a change in form (appearance) of stool 3. Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations  Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis) History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Clostridium Difficile Infection Aged >= 50 years on the day of Informed consent form had been signed and dated Attended all scheduled visits and complied with all trial procedures Covered by health insurance (if required) Must fulfill at least 1 of the following Risk Stratum 1 Had at least 2 hospital stays, each lasting at least >= 24 hours, in the 12 months before enrollment, and Had received systemic (not topical) antibiotics in the 12 months before enrollment, or Risk Stratum 2 Was anticipated to have an in-patient hospitalization for a planned surgical procedure within 60 days of enrollment. The impending hospital stay was planned to be >= 72 hours for a surgery involving 1 of the following Kidney/bladder/urinary system Musculoskeletal system  Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination) Participation in the 4 weeks preceding the first trial vaccination or participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure Receipt of any vaccine in the 4 weeks preceding the first trial vaccination except for influenza (seasonal or pandemic) and pneumococcal vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines Previous vaccination against C. difficile with either the trial vaccine, another vaccine, or monoclonal antibodies Diarrhea on day of enrollment Self-reported current or prior CDI episode Anticipated or current receipt of kidney dialysis treatment History of gastrointestinal surgery for gastrointestinal malignancy (Note: Colonoscopy, polypectomy, and appendectomy are not History of inflammatory bowel disease, irritable bowel syndrome (must diarrhea as a symptom), colostomy, or small or large intestine bowel surgery where resection was performed Receiving enteral feeding (e.g., nasogastric, gastrostomy, and jejunostomy tube feeding)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Dysmenorrhea Dysmenorrhea patients with a total dysmenorrhea score (sum of the two sub-scores: severity of dysmenorrhea and use of analgesics) of at least 3 points in each of the last two menstruations before randomization (baseline observation phase) Patients with dysmenorrheic pain during the 2 baseline cycles before randomization. Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with possible radiation towards back or thighs recorded in the Patient Diary in correspondence with a withdrawal and/or menstrual bleeding episode. Pain could start up to 2 days before the onset of the bleeding episode the bleeding and terminates on the last day of bleeding of before Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two menses before randomization (baseline observation phase) Willingness to use a barrier method (i.e., non-hormonal method) for contraception during the study. Acceptable methods of contraception (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device  Patients who have organic diseases of which surgical treatment is prioritized by the investigator Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in size of the longest diameters Patients with ovarian chocolate cysts having solid part in the cyst Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese Labeling)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Subject is at least 18 years old. 2. Subject has recurrent or relapsing CDI defined as At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g., rifaximin, nitazoxanide, fidaxomicin). OR At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity. OR Moderate CDI not responding to standard therapy (vancomycin) for at least a week. OR Severe C. difficile infection with toxic megacolon, not responding to standard therapy or the use of IVIg. 3. Subject is willing and able to provide informed consent. 4. If a female of childbearing potential, subject has agreed to use an acceptable form of birth control for up to 4 weeks after FMT treatment  Subject is pregnant. 2. Subject is unable to comply with study requirements
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Abdominal Pain Only patients referred to Pain Clinic for a trigger point injection Non-cancer pain greater than 3 months duration Unilateral abdominal pain Positive Carnett's sign (A test in which acute abdominal pain remains unchanged or increases when the muscles of the abdominal wall are tensed.) An identifiable abdominal trigger point  History of chronic psychotic disorder History of dementing illness Active abdominal visceral disease as a known contributor of the pain Abdominal surgery in the past 6 months More than one trigger point Abdominal wall hernias BMI>40